Onconic Therapeutics Reports 47.3 Billion Won in First-Half Sales, Up 154% Year-on-Year
First-Half Sales Reach 47.3 Billion Won, Operating Profit 7.4 Billion Won
Jakuvor Achieves 46.8 Billion Won in Prescriptions in First Half
July Prescription Sales Hit Record High of 9.7 Billion Won
Onconic Therapeutics reported significant increases in sales and operating profit in the first half of 2026, driven by expanded prescriptions for its new drug Jakuvor (ingredient name: Zastaprazan) for gastroesophageal reflux disease and revenue growth from overseas operations. The company is also expanding the development of additional indications for Jakuvor and research and development of Nesuparib, a next-generation anticancer drug candidate.
Onconic Therapeutics announced on August 12 that it recorded sales of 47.3 billion won and operating profit of 7.4 billion won in the first half of this year. Compared to the same period last year, sales increased by 154.3% and operating profit grew by 174.1%.
The main driver of this performance growth was Jakuvor, the company's proprietary new drug. According to the pharmaceutical market research firm Ubist, Jakuvor's prescription amount in the first half reached 46.8 billion won, up 171.6% from 17.2 billion won in the same period last year. On a quarterly basis, prescriptions increased from 21.2 billion won in the first quarter to 25.6 billion won in the second quarter. The uptrend in prescriptions has continued into the second half as well. In July, Jakuvor’s prescription sales reached approximately 9.7 billion won, marking its highest monthly figure since launch. Second-quarter operating profit was 2.8 billion won, down from 4.6 billion won in the first quarter, due to concentrated research and development (R&D) expenses for Jakuvor’s additional indication phase 3 trials and expanded clinical trials for Nesuparib in the second quarter.
Jakuvor currently holds approvals for two indications: erosive gastroesophageal reflux disease and the treatment of gastric ulcers. Onconic Therapeutics is conducting phase 3 clinical trials to expand indications, targeting non-erosive gastroesophageal reflux disease, Helicobacter pylori eradication therapy, and maintenance therapy following treatment of erosive gastroesophageal reflux disease. Nesuparib, the follow-up anticancer drug candidate, is undergoing phase 2 clinical trials for four types of cancer: pancreatic cancer, ovarian cancer, endometrial cancer, and gastric cancer.
Overseas business is also cited as a variable impacting performance. Jakuvor has entered 27 countries including China, India, and Central and South America; it recently obtained marketing authorization as a treatment for erosive gastroesophageal reflux disease in India. As approvals and commercialization proceed on a country-by-country basis in the future, milestone payments and royalty revenues from additional sales are expected to follow.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative of Onconic Therapeutics said, “In the first half of this year, the continued growth in domestic sales of Jakuvor was complemented by milestone revenue from overseas business, driving further sales growth. Based on the stable performance of Jakuvor, we will continue research and development of next-generation drug candidates such as Nesuparib.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.